Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

436
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
436
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

352
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
352
Nucleic Acids and Nucleotides01:20

Nucleic Acids and Nucleotides

16.4K
Nucleic acids are the most important macromolecules for the continuity of life. They carry the cell's genetic blueprint and have instructions for its functioning. The two main types of nucleic acids are deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).
Deoxyribonucleic Acid (DNA)
DNA is the genetic material in all living organisms, ranging from single-celled bacteria to multicellular mammals. It is in the nucleus of eukaryotes and the organelles such as chloroplasts and mitochondria....
16.4K
Nucleic Acids02:43

Nucleic Acids

52.0K
Nucleic acids are the most important macromolecules for the continuity of life. They carry the cell's genetic blueprint and carry instructions for its functioning.
DNA and RNA
The two main types of nucleic acids are deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). DNA is the genetic material in all living organisms, ranging from single-celled bacteria to multicellular mammals. It is in the nucleus of eukaryotes and in the organelles, chloroplasts, and mitochondria. In prokaryotes,...
52.0K
Nucleic acids02:43

Nucleic acids

197.5K
Nucleic acids are the most important macromolecules for the continuity of life. They carry the cell's genetic blueprint and carry instructions for its functioning.
DNA and RNA
The two main types of nucleic acids are deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). DNA is the genetic material in all living organisms, ranging from single-celled bacteria to multicellular mammals. It is in the nucleus of eukaryotes and in the organelles, chloroplasts, and mitochondria. In prokaryotes,...
197.5K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.4K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Critical considerations in the formulation development of parenteral biologic drugs.

Drug discovery today·2020
Same author

Feasibility of Freeze-Drying Oil-in-Water Emulsion Adjuvants and Subunit Proteins to Enable Single-Vial Vaccine Drug Products.

Journal of pharmaceutical sciences·2017
Same author

Obesity and risk of thyroid cancer: evidence from a meta-analysis of 21 observational studies.

Medical science monitor : international medical journal of experimental and clinical research·2015
Same author

Therapeutic effect of Cryptotanshinone on collagen-induced arthritis in rats via inhibiting nuclear factor kappa B signaling pathway.

Translational research : the journal of laboratory and clinical medicine·2015
Same author

Solitary subcutaneous gouty nodule mimicking metastatic melanoma on FDG PET/CT.

Clinical nuclear medicine·2015
Same author

Effects of nicotinamide N-methyltransferase on PANC-1 cells proliferation, metastatic potential and survival under metabolic stress.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology·2015

Related Experiment Video

Updated: Mar 28, 2026

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
09:41

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

25.8K

Critical considerations for developing nucleic acid macromolecule based drug products.

Bilikallahalli K Muralidhara1, Rinku Baid1, Steve M Bishop1

  • 1Formulation Sciences, Biopharmaceutical Development, Medimmune(4), One Medimmune Way, Gaithersburg, MD 20878, USA.

Drug Discovery Today
|December 18, 2015
PubMed
Summary

Developing stable formulations for nucleic acid macromolecules (NAMs) is crucial for effective protein expression therapy. This review outlines challenges and strategies for DNA/mRNA medicines, aiding therapeutic advancement.

More Related Videos

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
17:16

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring

Published on: December 9, 2010

11.0K
Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs
18:46

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs

Published on: December 9, 2010

13.8K

Related Experiment Videos

Last Updated: Mar 28, 2026

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
09:41

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

25.8K
Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
17:16

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring

Published on: December 9, 2010

11.0K
Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs
18:46

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs

Published on: December 9, 2010

13.8K

Area of Science:

  • Biotechnology and Pharmaceutical Sciences
  • Molecular Medicine
  • Drug Delivery Systems

Background:

  • Protein expression therapy using nucleic acid macromolecules (NAMs) presents a novel medical paradigm with significant therapeutic potential.
  • Nonviral delivery systems have enabled targeting of NAMs for diseases like cancer, immunodeficiency, and infectious diseases.
  • The complex and fragile nature of NAMs poses significant challenges for formulation and stability.

Purpose of the Study:

  • To review the challenges in formulating and ensuring the stability of DNA/mRNA-based medicines.
  • To discuss probable mitigation strategies for these formulation and stability challenges.
  • To provide a summary of delivery options for NAMs to target cells and compile a list of nucleic acid-based drugs in clinical trials.

Main Methods:

  • Literature review of formulation and stability challenges for DNA/mRNA medicines.
  • Synopsis of mitigation strategies for enhancing NAMs stability and delivery.
  • Compilation of nucleic acid-based drugs currently in clinical trials.

Main Results:

  • Identified key challenges in developing stable formulations for NAMs, impacting shelf-life and efficacy.
  • Outlined various strategies to overcome formulation and stability hurdles for DNA/mRNA therapeutics.
  • Summarized diverse delivery options and presented an overview of ongoing clinical trials for nucleic acid-based drugs.

Conclusions:

  • Overcoming formulation and stability challenges is critical for realizing the full therapeutic potential of NAMs.
  • Advancements in delivery systems and formulation strategies are essential for successful protein expression therapy.
  • The ongoing clinical trials highlight the growing importance and promise of nucleic acid-based medicines.